Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



Phase 1 / 2 Study of LOXO-292 in Patients With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer

Miscellaneous

This is a Phase 1 / 2, open-label, first-in-human study designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity of selpercatinib (also known as LOXO-292) administered orally to patients with advanced solid tumors, including RET-fusion-positive solid tumors, medullary thyroid cancer (MTC) and other tumors with RET activation.
Miscellaneous
I/II
Berlin, Jordan
NCT03157128
VICCPHI1873

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: